We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Read MoreHide Full Article
Shares of biotechnology company Rigel Pharmaceuticals, Inc. (RIGL - Free Report) have surged 41.4% in the past year against the industry’s decline of 13.4%. The stock also outperformed the sector and S&P 500 Index during this time frame.
The outperformance can be attributed to the strong growth of leading drug, Tavalisse, and an impressive pipeline progress.
RIGL Outperforms Industry, Sector and Industry
Image Source: Zacks Investment Research
Tavalisse Growth Boosts RIGL’s Top Line
Rigel’s first approved product Tavalisse (fostamatinib disodium hexahydrate) showed encouraging uptake in 2024. The drug is the only approved oral SYK inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug is also approved in the EU, UK and Japan.
Last month, Rigel provided a business update and outlook for 2025. Tavalisse generated $104.8 million in net product sales in 2024.
Rigel is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AM R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. Rigel in-licensed the drug from Forma with exclusive, worldwide rights for its development, manufacturing and commercialization.
Rigel entered into an exclusive license agreement with Dr. Reddy's (RDY - Free Report) in November to develop and commercialize the drug in all potential indications throughout Dr. Reddy's territory, which includes Latin America, South Africa, certain countries in the Commonwealth of Independent States (CIS), India, certain countries in Southeast Asia and North Africa, Australia and New Zealand.
Rigel is entitled to receive an upfront cash payment of $4.0 million from RDY with the potential for up to $36.0 million in future regulatory and commercial milestone payments.
The company added a third product, Gavreto, to its commercial portfolio in 2024. The drug was added to RIGL’s portfolio after the company acquired commercial rights of the drug from Blueprint Medicines Corporation (BPMC - Free Report) . Gavreto became commercially available from Rigel in June 2024. The drug's incremental contribution boosted the company's top line in 2024.
RIGL Makes Impressive Pipeline Progress
Apart from these approved drugs, RIGL is developing other drugs, and the pipeline progress has been encouraging.
Last month, the FDA granted Orphan Drug designation to R289, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, for the treatment of myelodysplastic syndromes (MDS). RIGL is evaluating the candidate in an ongoing phase Ib study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with lower-risk myelodysplastic syndromes (LR-MDS) who are relapsed or refractory to prior therapies.
The candidate was also granted Fast Track designation by the regulatory body for this indication.
RIGL also announced that the first patient was enrolled in a phase Ib/II triplet therapy trial of decitabine and venetoclax in combination with Rezlidhia in patients with mIDH1 AML. The study is being sponsored and conducted by The University of Texas MD Anderson Cancer Center.
RIGL’s Upbeat 2025 Outlook
Rigel anticipates total revenues of approximately $200-$210 million in 2025, including product sales of approximately $185-$192 million. The company also expects to report positive net income in 2025 while funding existing and new clinical development programs.
RIGL’s Valuation and Estimate Movement
Going by the price/sales ratio, RIGL’s shares currently trade at 1.74x forward sales, lower than its mean of 2.38x but higher than 1.64x for the drug industry.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share (EPS) has gone up to 22 cents from 17 cents over the past 60 days. The EPS estimate for 2025 has also jumped 13 cents to $1.05.
Image Source: Zacks Investment Research
Invest in RIGL Stock
We are optimistic about RIGL, buoyed by its strong performance in 2024 and upbeat guidance for 2025. Growth in Tavalisse sales should fuel top line. Contributions from its other drugs should also boost the top line.
Given RIGL's current valuation, we believe there is more room for growth and recommend prospective investors to add the stock to their portfolio.
Image: Bigstock
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Shares of biotechnology company Rigel Pharmaceuticals, Inc. (RIGL - Free Report) have surged 41.4% in the past year against the industry’s decline of 13.4%. The stock also outperformed the sector and S&P 500 Index during this time frame.
The outperformance can be attributed to the strong growth of leading drug, Tavalisse, and an impressive pipeline progress.
RIGL Outperforms Industry, Sector and Industry
Image Source: Zacks Investment Research
Tavalisse Growth Boosts RIGL’s Top Line
Rigel’s first approved product Tavalisse (fostamatinib disodium hexahydrate) showed encouraging uptake in 2024. The drug is the only approved oral SYK inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug is also approved in the EU, UK and Japan.
Last month, Rigel provided a business update and outlook for 2025. Tavalisse generated $104.8 million in net product sales in 2024.
Rigel is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AM R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. Rigel in-licensed the drug from Forma with exclusive, worldwide rights for its development, manufacturing and commercialization.
Rigel entered into an exclusive license agreement with Dr. Reddy's (RDY - Free Report) in November to develop and commercialize the drug in all potential indications throughout Dr. Reddy's territory, which includes Latin America, South Africa, certain countries in the Commonwealth of Independent States (CIS), India, certain countries in Southeast Asia and North Africa, Australia and New Zealand.
Rigel is entitled to receive an upfront cash payment of $4.0 million from RDY with the potential for up to $36.0 million in future regulatory and commercial milestone payments.
The company added a third product, Gavreto, to its commercial portfolio in 2024. The drug was added to RIGL’s portfolio after the company acquired commercial rights of the drug from Blueprint Medicines Corporation (BPMC - Free Report) . Gavreto became commercially available from Rigel in June 2024. The drug's incremental contribution boosted the company's top line in 2024.
RIGL Makes Impressive Pipeline Progress
Apart from these approved drugs, RIGL is developing other drugs, and the pipeline progress has been encouraging.
Last month, the FDA granted Orphan Drug designation to R289, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, for the treatment of myelodysplastic syndromes (MDS). RIGL is evaluating the candidate in an ongoing phase Ib study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with lower-risk myelodysplastic syndromes (LR-MDS) who are relapsed or refractory to prior therapies.
The candidate was also granted Fast Track designation by the regulatory body for this indication.
RIGL also announced that the first patient was enrolled in a phase Ib/II triplet therapy trial of decitabine and venetoclax in combination with Rezlidhia in patients with mIDH1 AML. The study is being sponsored and conducted by The University of Texas MD Anderson Cancer Center.
RIGL’s Upbeat 2025 Outlook
Rigel anticipates total revenues of approximately $200-$210 million in 2025, including product sales of approximately $185-$192 million. The company also expects to report positive net income in 2025 while funding existing and new clinical development programs.
RIGL’s Valuation and Estimate Movement
Going by the price/sales ratio, RIGL’s shares currently trade at 1.74x forward sales, lower than its mean of 2.38x but higher than 1.64x for the drug industry.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share (EPS) has gone up to 22 cents from 17 cents over the past 60 days. The EPS estimate for 2025 has also jumped 13 cents to $1.05.
Image Source: Zacks Investment Research
Invest in RIGL Stock
We are optimistic about RIGL, buoyed by its strong performance in 2024 and upbeat guidance for 2025. Growth in Tavalisse sales should fuel top line. Contributions from its other drugs should also boost the top line.
Given RIGL's current valuation, we believe there is more room for growth and recommend prospective investors to add the stock to their portfolio.
RIGL currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.